Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza a and B viruses
Antiviral Res. 2023 Aug 9:105701. doi: 10.1016/j.antiviral.2023.105701. Online ahead of print.ABSTRACTNeuraminidase inhibitors (NAIs) are recommended for influenza treatment and prevention worldwide. The most widely prescribed NAI is oral oseltamivir, while inhaled zanamivir is less commonly used. Using phenotypic neuraminidase (NA) enzymatic assays and molecular modeling approaches, we examined the ability of the investigational orally-dosed NAI AV5080 to inhibit viruses of the influenza A (H1N1)pdm09, A (H3N2), A (H5N1), and A (H7N9) subtypes and the influenza B/Victoria- and B/Yamagata-lineages containing NA substitutio...
Source: Antiviral Research - August 11, 2023 Category: Virology Authors: Andrei A Ivashchenko Jeremy C Jones Dmitry O Shkil Yan A Ivanenkov Philippe Noriel Q Pascua Melissa Penaflor Ruben N Karapetian Elena A Govorkova Alexandre V Ivachtchenko Source Type: research
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses
Antiviral Res. 2023 Aug 9;217:105701. doi: 10.1016/j.antiviral.2023.105701. Online ahead of print.ABSTRACTNeuraminidase inhibitors (NAIs) are recommended for influenza treatment and prevention worldwide. The most widely prescribed NAI is oral oseltamivir, while inhaled zanamivir is less commonly used. Using phenotypic neuraminidase (NA) enzymatic assays and molecular modeling approaches, we examined the ability of the investigational orally-dosed NAI AV5080 to inhibit viruses of the influenza A(H1N1)pdm09, A(H3N2), A(H5N1), and A(H7N9) subtypes and the influenza B/Victoria- and B/Yamagata-lineages containing NA substitutio...
Source: Antiviral Research - August 11, 2023 Category: Virology Authors: Andrei A Ivashchenko Jeremy C Jones Dmitry O Shkil Yan A Ivanenkov Philippe Noriel Q Pascua Melissa K Penaflor Ruben N Karapetian Elena A Govorkova Alexandre V Ivachtchenko Source Type: research
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses
Antiviral Res. 2023 Aug 9;217:105701. doi: 10.1016/j.antiviral.2023.105701. Online ahead of print.ABSTRACTNeuraminidase inhibitors (NAIs) are recommended for influenza treatment and prevention worldwide. The most widely prescribed NAI is oral oseltamivir, while inhaled zanamivir is less commonly used. Using phenotypic neuraminidase (NA) enzymatic assays and molecular modeling approaches, we examined the ability of the investigational orally-dosed NAI AV5080 to inhibit viruses of the influenza A(H1N1)pdm09, A(H3N2), A(H5N1), and A(H7N9) subtypes and the influenza B/Victoria- and B/Yamagata-lineages containing NA substitutio...
Source: Antiviral Research - August 11, 2023 Category: Virology Authors: Andrei A Ivashchenko Jeremy C Jones Dmitry O Shkil Yan A Ivanenkov Philippe Noriel Q Pascua Melissa K Penaflor Ruben N Karapetian Elena A Govorkova Alexandre V Ivachtchenko Source Type: research
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses
Antiviral Res. 2023 Aug 9;217:105701. doi: 10.1016/j.antiviral.2023.105701. Online ahead of print.ABSTRACTNeuraminidase inhibitors (NAIs) are recommended for influenza treatment and prevention worldwide. The most widely prescribed NAI is oral oseltamivir, while inhaled zanamivir is less commonly used. Using phenotypic neuraminidase (NA) enzymatic assays and molecular modeling approaches, we examined the ability of the investigational orally-dosed NAI AV5080 to inhibit viruses of the influenza A(H1N1)pdm09, A(H3N2), A(H5N1), and A(H7N9) subtypes and the influenza B/Victoria- and B/Yamagata-lineages containing NA substitutio...
Source: Antiviral Research - August 11, 2023 Category: Virology Authors: Andrei A Ivashchenko Jeremy C Jones Dmitry O Shkil Yan A Ivanenkov Philippe Noriel Q Pascua Melissa K Penaflor Ruben N Karapetian Elena A Govorkova Alexandre V Ivachtchenko Source Type: research
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses
Antiviral Res. 2023 Aug 9;217:105701. doi: 10.1016/j.antiviral.2023.105701. Online ahead of print.ABSTRACTNeuraminidase inhibitors (NAIs) are recommended for influenza treatment and prevention worldwide. The most widely prescribed NAI is oral oseltamivir, while inhaled zanamivir is less commonly used. Using phenotypic neuraminidase (NA) enzymatic assays and molecular modeling approaches, we examined the ability of the investigational orally-dosed NAI AV5080 to inhibit viruses of the influenza A(H1N1)pdm09, A(H3N2), A(H5N1), and A(H7N9) subtypes and the influenza B/Victoria- and B/Yamagata-lineages containing NA substitutio...
Source: Antiviral Research - August 11, 2023 Category: Virology Authors: Andrei A Ivashchenko Jeremy C Jones Dmitry O Shkil Yan A Ivanenkov Philippe Noriel Q Pascua Melissa K Penaflor Ruben N Karapetian Elena A Govorkova Alexandre V Ivachtchenko Source Type: research
Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses
Antiviral Res. 2023 Aug 9;217:105701. doi: 10.1016/j.antiviral.2023.105701. Online ahead of print.ABSTRACTNeuraminidase inhibitors (NAIs) are recommended for influenza treatment and prevention worldwide. The most widely prescribed NAI is oral oseltamivir, while inhaled zanamivir is less commonly used. Using phenotypic neuraminidase (NA) enzymatic assays and molecular modeling approaches, we examined the ability of the investigational orally-dosed NAI AV5080 to inhibit viruses of the influenza A(H1N1)pdm09, A(H3N2), A(H5N1), and A(H7N9) subtypes and the influenza B/Victoria- and B/Yamagata-lineages containing NA substitutio...
Source: Antiviral Research - August 11, 2023 Category: Virology Authors: Andrei A Ivashchenko Jeremy C Jones Dmitry O Shkil Yan A Ivanenkov Philippe Noriel Q Pascua Melissa K Penaflor Ruben N Karapetian Elena A Govorkova Alexandre V Ivachtchenko Source Type: research
Treatment and prevention of influenza in geriatric patients
Expert Rev Clin Pharmacol. 2023 Aug 1. doi: 10.1080/17512433.2023.2243221. Online ahead of print.ABSTRACTINTRODUCTION: Older adults are the most vulnerable population to the effects of influenza. These patients have age-related characteristics that make response to both infection and therapeutics different than younger patients.AREAS COVERED: Influenza vaccination and antiviral therapy are the foundational approach to preventing and treating influenza in geriatric patients. Older adults should receive one of three enhanced vaccines before influenza season beings. There are five antivirals used in influenza. Geriatric patie...
Source: Pharmacological Reviews - August 1, 2023 Category: Drugs & Pharmacology Authors: Marilyn N Bulloch Source Type: research
Treatment and prevention of influenza in geriatric patients
Expert Rev Clin Pharmacol. 2023 Aug 1. doi: 10.1080/17512433.2023.2243221. Online ahead of print.ABSTRACTINTRODUCTION: Older adults are the most vulnerable population to the effects of influenza. These patients have age-related characteristics that make response to both infection and therapeutics different than younger patients.AREAS COVERED: Influenza vaccination and antiviral therapy are the foundational approach to preventing and treating influenza in geriatric patients. Older adults should receive one of three enhanced vaccines before influenza season beings. There are five antivirals used in influenza. Geriatric patie...
Source: Expert Review of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Authors: Marilyn N Bulloch Source Type: research
Treatment and prevention of influenza in geriatric patients
Expert Rev Clin Pharmacol. 2023 Aug 1. doi: 10.1080/17512433.2023.2243221. Online ahead of print.ABSTRACTINTRODUCTION: Older adults are the most vulnerable population to the effects of influenza. These patients have age-related characteristics that make response to both infection and therapeutics different than younger patients.AREAS COVERED: Influenza vaccination and antiviral therapy are the foundational approach to preventing and treating influenza in geriatric patients. Older adults should receive one of three enhanced vaccines before influenza season beings. There are five antivirals used in influenza. Geriatric patie...
Source: Pharmacological Reviews - August 1, 2023 Category: Drugs & Pharmacology Authors: Marilyn N Bulloch Source Type: research
Treatment and prevention of influenza in geriatric patients
Expert Rev Clin Pharmacol. 2023 Aug 1. doi: 10.1080/17512433.2023.2243221. Online ahead of print.ABSTRACTINTRODUCTION: Older adults are the most vulnerable population to the effects of influenza. These patients have age-related characteristics that make response to both infection and therapeutics different than younger patients.AREAS COVERED: Influenza vaccination and antiviral therapy are the foundational approach to preventing and treating influenza in geriatric patients. Older adults should receive one of three enhanced vaccines before influenza season beings. There are five antivirals used in influenza. Geriatric patie...
Source: Expert Review of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Authors: Marilyn N Bulloch Source Type: research
Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19
CONCLUSION: In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues and the influence of these pronouncing drugs over these sequences. The outcome of this research work provides researchers with a track record for carrying out further investigational procedures by applying docking simulations and in vitro and in vivo experimentation with these reprofile drugs so that a better drug can be formulated against coronavirus.PMID:37515684 | DOI:10.1007/s11845-023-03473-9 (Source: Molecular Medicine)
Source: Molecular Medicine - July 29, 2023 Category: Molecular Biology Authors: Wajeeha Waseem Rehman Zafar Muhammad Saeed Jan Taghrid S Alomar Najla Almasoud Abdur Rauf Humayoon Khattak Source Type: research
Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19
CONCLUSION: In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues and the influence of these pronouncing drugs over these sequences. The outcome of this research work provides researchers with a track record for carrying out further investigational procedures by applying docking simulations and in vitro and in vivo experimentation with these reprofile drugs so that a better drug can be formulated against coronavirus.PMID:37515684 | DOI:10.1007/s11845-023-03473-9 (Source: Molecular Medicine)
Source: Molecular Medicine - July 29, 2023 Category: Molecular Biology Authors: Wajeeha Waseem Rehman Zafar Muhammad Saeed Jan Taghrid S Alomar Najla Almasoud Abdur Rauf Humayoon Khattak Source Type: research
Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19
ConclusionIn our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues and the influence of these pronouncing drugs over these sequences. The outcome of this research work provides researchers with a track record for carrying out further investigational procedures by applying docking simulations and in vitro and in vivo experimentation with these reprofile drugs so that a better drug can be formulated against coronavirus. (Source: Irish Journal of Medical Science)
Source: Irish Journal of Medical Science - July 29, 2023 Category: General Medicine Source Type: research
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022
Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679. Online ahead of print.ABSTRACTClade 2.3.4.4 b highly pathogenic avian influenza (HPAI) A (H5N1) viruses that are responsible for devastating outbreaks in birds and mammals pose a potential threat to public health. Here, we evaluated their susceptibility to influenza antivirals. Of 1015 sequences of HPAI A (H5N1) viruses collected in the United States during 2022, eight viruses (∼0.8%) had a molecular marker of drug resistance to an FDA-approved antiviral: three adamantane-resistant (M2-V27A), four oseltamivir-resistant (NA-H275Y), and one baloxavir-...
Source: Antiviral Research - July 26, 2023 Category: Virology Authors: Ha T Nguyen Anton Chesnokov Juan De La Cruz Philippe Noriel Q Pascua Vasiliy P Mishin Yunho Jang Joyce Jones Han Di Andrei A Ivashchenko Mary Lea Killian Mia K Torchetti Kristina Lantz David E Wentworth Charles T Davis Alexandre V Ivachtchenko Larisa V Gu Source Type: research
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022
Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679. Online ahead of print.ABSTRACTClade 2.3.4.4 b highly pathogenic avian influenza (HPAI) A (H5N1) viruses that are responsible for devastating outbreaks in birds and mammals pose a potential threat to public health. Here, we evaluated their susceptibility to influenza antivirals. Of 1015 sequences of HPAI A (H5N1) viruses collected in the United States during 2022, eight viruses (∼0.8%) had a molecular marker of drug resistance to an FDA-approved antiviral: three adamantane-resistant (M2-V27A), four oseltamivir-resistant (NA-H275Y), and one baloxavir-...
Source: Cell Research - July 26, 2023 Category: Cytology Authors: Ha T Nguyen Anton Chesnokov Juan De La Cruz Philippe Noriel Q Pascua Vasiliy P Mishin Yunho Jang Joyce Jones Han Di Andrei A Ivashchenko Mary Lea Killian Mia K Torchetti Kristina Lantz David E Wentworth Charles T Davis Alexandre V Ivachtchenko Larisa V Gu Source Type: research
